Introduction {#Sec1}
============

Gastrointestinal stromal tumours (GISTs) are a rare malignancy, accounting for less than 1% of all cancers of the gastrointestinal (GI) tract \[[@CR1]\] and in Europe the annual incidence is 15 cases per million population \[[@CR2]\]. They are a distinct tumour type arising from the interstitial cells of Cajal (ICC), characterised in 96% of cases by the expression of the receptor tyrosine kinase KIT (CD117) protein (demonstrable on immunohistochemistry) \[[@CR3]\]. The 4% of GIST cases that are KIT negative \[[@CR4], [@CR5]\] are more likely to contain platelet-derived growth factor receptor alpha (PDGFRA) mutations \[[@CR4]\], and this and alternative markers (e.g. DOG1) can be used to enable diagnosis if KIT immunochemistry is negative \[[@CR2]\].

Within the past decade, imatinib (at doses of 400 to 800 mg/day) and sunitinib have been licensed for the treatment of GIST. Prior to this, 'best supportive care' (e.g. to control symptoms and pain) was the only available treatment for those with unresectable disease. The prognosis for this patient group was poor, with few patients surviving 2 years \[[@CR6], [@CR7]\].

Management of unresectable and/or metastatic GIST typically involves commencing patients on the standard imatinib dose of 400 mg/day. On confirmed disease progression at this dose, decisions regarding treatment depend on the individual's clinical circumstances, but options can include dose escalation of imatinib up to an 800 mg/day dose, sunitinib (within its licensed dose range) or best supportive care \[[@CR3], [@CR8]--[@CR10]\].

Response to imatinib is more likely in GISTs with certain pathogenic KIT mutations. This could provide predictive biomarkers to enable the personalisation and optimisation of first- and second-line therapy \[[@CR11]\]. In a recent meta-analysis of RCTs comparing first-line use of standard 400 mg/day imatinib with an initial 800 mg/day dose, those with exon nine mutations had longer progression-free survival (*p* = 0.017), but not overall survival (*p* = 0.150) in the 800 mg/day arm. This suggests the possibility that patients with exon 9 mutations may benefit from immediate high dose imatinib treatment, as opposed to escalation only upon disease progression \[[@CR12]\].

However, even if individually tailored imatinib starting doses, based on the identification of KIT mutations (or other biomarkers), become standard clinical practice in future, evidence on the effectiveness of escalated imatinib doses in unresectable or metastatic disease following progression on the 400 mg/day dose is still relevant. This is because all patients eventually progress after an initial response and for those on 400 mg/day, dose escalation remains an available option \[[@CR13]--[@CR17]\]. Some of the clinically relevant molecular mechanisms for secondary resistance to imatinib 400 mg/day have also recently been identified, and secondary mutations in KIT exons 13, 14, 17, and 18 are associated with acquired resistance to imatinib \[[@CR15]\], which may also impact on the effectiveness of imatinib dose escalation.

The objective of this review was to determine the relative benefit (in patients who have acquired resistance to the 400 mg/day imatinib dose) of dose escalation (to either 600 mg/day or 800 mg/day imatinib), sunitinib or best supportive care.

Materials and Methods {#Sec2}
=====================

Electronic searches of relevant databases were undertaken to identify reports of published and ongoing studies. The searches were designed to be sensitive, using both controlled vocabulary and text terms. Full details of the search strategies used can be obtained from the authors. The databases searched were: Medline (1966---September Wk 3 2009), Medline In-Process (25th September 2009), Embase (1980---Week 39 2009), CINAHL (September 2009), Science Citation Index (2000---26th September 2009), Biosis (2000---24th September 2009), Health Management Information Consortium (September 2009), and the Cochrane Controlled Trials Register for primary research and the Database of Abstracts of Reviews of Effects (DARE) (October 2009), the Cochrane Database of Systematic Reviews (CDSR; Issue 3 2009) and the HTA database for relevant evidence syntheses (October 2009).

Ongoing and recently completed trials were identified from current research registers, including Clinical Trials, Current Controlled Trials, NIHR Portfolio, WHO International Clinical Trials Registry Platform, IFPMA Clinical Trials and the ABPI database. Recent conference proceedings of key oncology and gastrointestinal organisations, including the American Society for Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO) and the European Cancer Organisation were also searched. Websites of the GIST Support International, and the drug manufacturers, Pfizer (sunitinib) and Novartis (imatinib), were also scrutinised as were the reference lists of retrieved papers, in order to identify additional potentially relevant studies.

Randomised controlled trials (RCTs), non-randomised comparative studies and case series were all considered relevant and non-English language studies were permitted. Studies of animal models, preclinical and biological studies, reviews, editorials, opinions, case reports and reports investigating technical aspects of the interventions were excluded.

The population of interest was adults with KIT-positive unresectable and/or metastatic gastrointestinal stromal tumours (GIST), whose disease had progressed on treatment with imatinib on 400 mg/day. Subgroup analysis was to be undertaken (if data were available) on patients with differing KIT mutations.

The interventions under consideration were imatinib at escalated doses of 600 mg/day or 800 mg/day, being prescribed in addition to best supportive care, which was defined to include active symptom control, pain management and "the multi-professional attention to the individual's overall physical, psychosocial, spiritual and cultural needs" \[[@CR18]\]. The comparators considered were sunitinib (prescribed within its recommended dose range of 25--75 mg/day and provided in addition to best supportive care), and best supportive care alone.

Included studies were required to report at least one of the following outcomes: overall response, overall survival, disease-free survival, progression-free survival, time to treatment failure, health-related quality of life or the adverse effects of treatment.

Two reviewers independently screened titles and abstracts of all records identified by the searches and assessed full-text copies of all potentially relevant reports against the pre-defined inclusion criteria. Screening and data extraction forms were developed to assist in obtaining relevant information. Data extraction was undertaken by two reviewers; dual data extraction was not conducted but both reviewers were trained in data extraction and therefore inter-rater reliability was expected to be good \[[@CR19]\].

Two reviewers also independently assessed the methodological quality of the included full-text studies, utilising an 18-question checklist that was adapted from several sources \[[@CR20]--[@CR22]\]. Included conference abstracts were not quality assessed because they were considered unlikely to provide sufficient methodological information to enable an accurate assessment of study quality.

All disagreements between reviewers during screening and quality assessment were resolved by discussion and consensus. No arbitration by a third party was necessary.

Data analysis methods for circumstances where sufficient evidence for quantitative synthesis were available was initially planned but where this was not considered feasible (e.g. due to insufficient available evidence) a narrative synthesis of results was conducted.

Results {#Sec3}
=======

Search Results and Studies Included {#Sec4}
-----------------------------------

A flow diagram of the search results and screening process is outlined in Fig. [1](#Fig1){ref-type="fig"}. Six full-text papers \[[@CR13], [@CR17], [@CR23]--[@CR26]\] and ten abstracts \[[@CR27]--[@CR36]\] reporting the results of four trials and one additional retrospective cohort, met our inclusion criteria. The main reason for the exclusion of full-text papers not meeting the review inclusion criteria are provided in Table [1](#Tab1){ref-type="table"}.Fig. 1Flow diagram outlining the screening process for the review of clinical effectivenessTable 1Reasons for exclusion of studiesReason for exclusionNumber of studies excludedPatient had resectable GIST24Outcomes not reported separately for GIST patients10\<10 patients in relevant study population46Imatinib dose is 400 mg/day13No/insufficient data reported for escalated dose patients66No imatinib dose reported84No relevant interventions15Treatment not evaluated11No outcomes of relevance10Other reason61340Retained for background information49Review articles169Letter/editorial/correspondence/symposium articles/meeting reports/expert views/comments117Case study/case series \<10 patients64Non-English language exclusions123Not obtained47Total909

Corresponding authors were contacted for nine studies (reported in a total of 14 papers) to clarify and determine study inclusion or exclusion. Four authors (28.6%) responded. In three instances the studies were excluded (personal communication, P Rutkowski and P Wolter, Jan 2010) and in one instance \[[@CR26]\], the study was included. It was necessary to exclude the remaining ten papers, as clarification was not provided \[[@CR37]--[@CR41]\].

No RCTs or non-randomised comparative studies were found that directly compared the effectiveness of imatinib at escalated doses (600 or 800 mg/day) with either sunitinib or best supportive care. One on-going trial comparing an escalated imatinib dose with sunitinib was identified, but this trial had been stopped due to poor recruitment \[[@CR42]\].

Relevant data were reported in five full-text reports of three RCTs. These were:EORTC-ISG-AGITG (62005) trial, as reported by Zalcberg and colleagues \[[@CR17]\] and Debiec-Rychter and colleagues \[[@CR24]\], with one additional abstract reporting interim data \[[@CR36]\].S0033 trial as reported by Blanke and colleagues \[[@CR13]\], with two additional abstracts reporting interim data \[[@CR27], [@CR29]\].B2222 trial as reported by Blanke and colleagues \[[@CR23]\], and Demetri and colleagues \[[@CR43]\].

Each trial compared randomisation to 400 mg/day imatinib with randomisation to a high (e.g. 600 mg/day or 800 mg/day) dose. Each of these papers reported separate data on the outcomes of patients initially randomised to 400 mg/day who went on to receive an escalated dose only upon progression at this dose. As these participants were randomised to the 400 mg/day arm but were not further randomised to an escalated dose on progression, the data are essentially observational even though they are derived from RCTs.

The escalated dose for the EORTC-ISG-AGITG and S0033 trials was 800 mg/day \[[@CR13], [@CR17]\], while for the B2222 trial it was 600 mg/day \[[@CR23]\].

In addition, one full-text paper of a non-randomised retrospective study by Park and colleagues, was also included, as it contained data on two groups of patients receiving each of the escalated doses upon progression at 400 mg/day \[[@CR26]\].

For sunitinib, seven abstracts met the inclusion criteria \[[@CR28], [@CR30]--[@CR35]\]. All related to an on-going, open-label sunitinib trial reporting information on participants recruited to the trial following failure at a variety of different doses of imatinib, and reported separate information for a prior imatinib dose of ≤400 mg/day. The abstract by Seddon and colleagues \[[@CR35]\] was considered the most recent and therefore designated the primary report for this study.

Corresponding authors of each included trial were contacted to determine whether any additional data could be provided for the relevant study population within the timeframe of this review. Data for the S0033 trial were provided by the authors (personal communication, C Rankin, February 2010).

Data were extracted for all outcomes of interest. No study reported data on disease-free survival or health-related quality of life. Baseline characteristics for the relevant study population (i.e. those who received escalated imatinib doses) were reported in two studies \[[@CR17], [@CR26]\].

Results of the quality assessment are provided in Fig. [2](#Fig2){ref-type="fig"}. Study quality was similar for all imatinib studies, though assessment was complicated as the population of interest was a subgroup within each trial and therefore data were observational. None of the studies had a consecutive sample selection, had considered all the important outcomes of relevance or blinded outcome assessment, or had clearly adjusted for confounding factors. However, all had used valid and reliable outcome measures, described inclusion and exclusion criteria, and the interventions clearly and had collected data prospectively. Assessment with the remaining quality criteria was unclear for all studies or varied between studies.Fig. 2Quality assessment of included full-text papers

Clinical Outcome Results for Dose Escalation of Imatinib or Sunitinib {#Sec5}
---------------------------------------------------------------------

Outcome results reported for each of the included imatinib studies are provided in Table [2](#Tab2){ref-type="table"}. Additional data on specific adverse events were provided for the relevant study population only for the EORTC-ISG-AGITG trial \[[@CR17]\]. Following dose escalation to 800 mg/day, a significantly lower rate of neutropenia was observed (*p* = 0.002). However, among the same population, significantly higher rates of anaemia and fatigue (*p* = 0.015 and *p* \< 0.001, respectively) were observed \[[@CR17]\].Table 2Results from included imatinib studiesDrug (dose)Imatinib (600 mg/day)Imatinib (800 mg/day)StudyPark et al. \[[@CR26]\]B2222 \[[@CR23]\]Park et al. \[[@CR26]\]S0033 \[[@CR13]\]EORTC-ISG-AGITG \[[@CR17]\]Number receiving escalated dose124312118133Median follow up (range)8 months (1.4 to 22.3 months)63 months (NR-71 months)8 months (1.4 to 22.3 months)54 months (NR)25 months (NR to 35 months)N (%) with responseNRNRNR3/117 (2.6%)3/133 (2.3%)N (%) with stable diseaseNRNRNR33/117 (28.2%)36/133 (27.0%)Total N(%) with response or stable disease5/12 (41.7%)11/43 (25.6%)^b^4/12 (33.3%)36/117 (30.8%)39/133 (29.3%)Median overall survival (95% CI)^a^NRNRNR19 months (13 to 23 months)NRN (%) still aliveNRNRNR42/118 (35.6%)NRProgression-free survival (95% CI)^a^NRNRNR5 months (2 to 10 months)2.9 months (not reported)N (%) progression freeNRNRNR19/118 (16.1%)25/133 (18.8%)Median duration of "stabilisation"/time to progression1.7 months (range: 0.7 to 24.9 months)NRNRNR5.5 months (range: 1.3 to 20.5 months)^d^Disease free survivalNRNRNRNRNRHealth related quality of lifeNRNRNRNRNRN (%) discontinuations due to adverse eventsNRNRNRNR11/97 (11.6%)^c^N(%) with ≥1 dose delayNRNRNR18/77 (23.3%)NRN(%) with ≥1 dose reductionNRNRNR12/77 (15.6%)NR (31%)*NR* not reported^a^Unless explicitly stated to be a reported range^b^One patient only achieved response/stable disease following further dose escalation to 800 mg/day^c^Figure estimated from data reported in the paper^d^Unit of measurements has been converted to months by dividing by 28 (for days), dividing by 4 (weeks), or multiplying by 12 (years)

With regard to mutational analysis, Debiec-Rychter and colleagues in secondary analysis for the EORTC-ISG-AGITG trial demonstrated that response following dose escalation was significantly more likely to occur in patients with wild-type KIT GISTs compared with those with KIT exon 11 mutations (*p* = 0.0012), and was also significantly more likely to occur in patients with KIT exon 9 mutations compared with KIT exon 11 mutations (*p* = 0.0017), though no figures were reported for the number of patients involved \[[@CR24]\].

For sunitinib, overall survival was reported by Seddon and colleagues as being 90 weeks (95% CI 73 to 106 weeks) for those receiving sunitinib upon progression with an imatinib dose of ≤400 mg/day. However, the median follow up time (51 weeks, 95% CI 0.1 to 159 weeks) was only available for the entire study population (i.e. regardless of prior imatinib dose). Of those receiving sunitinib after progression on the ≤400 mg/day imatinib dose 193/351 (55%) were still alive at the time of analysis \[[@CR35]\].

Overall survival with the escalated 800 mg/day dose of imatinib was compared with sunitinib at a dose of 50 mg for patients who had progressed on imatinib at a dose of ≤400 mg/day using data for the S0033 trial provided by authors, and quarterly overall survival estimates reported in a Kaplan--Meier chart by Seddon and colleagues, employing the method proposed by Parmar and colleagues \[[@CR44]\] (Fig. [3](#Fig3){ref-type="fig"}). A meta-analysis of available Kaplan--Meier data for progression-free survival for the EORTC-ISG-AGITG and S0033 trials of the escalated 800 mg/day imatinib dose was attempted using the method described by Arends and colleagues \[[@CR45]\], but was not possible due to lack of data. A visual description of the progression-free survival results from these studies is provided in Fig. [4](#Fig4){ref-type="fig"}.Fig. 3Comparison of overall survival estimates for imatinib at 800 mg/day \[[@CR13]\] and sunitinib at 50 mg \[[@CR34]\]Fig. 4Comparison between two studies of progression free survival estimates with imatinib at 800 mg/day \[[@CR13], [@CR17]\]

Discussion {#Sec6}
==========

This systematic review was performed to address the question: "What is the most effective management strategy for patients with advanced GISTs who have progressed following initial therapy with imatinib 400 mg/day?" Dose escalation of imatinib, sunitinib, and best supportive care were the options considered. The review of the evidence base was detailed and thorough, and a large number of full-text papers were assessed against the inclusion criteria. Non-English language studies were reviewed, and attempts were made to contact study authors for clarification and additional data.

The data show that following dose escalation of imatinib, approximately one-third of patients achieved a partial response or stable disease. Over a median follow-up of over 2 years, more than half (i.e. 44/75 or 58.7%) of those who showed response or stable disease on the 800 mg/day escalated dose remained progression free. Dose escalation appeared to be well tolerated, for most patients, although more fatigue and myelosuppression were observed.

Overall survival was less than 2 years for both those receiving the 800 mg/day imatinib dose and those receiving sunitinib. However, given the nature of the evidence base it is difficult to draw any conclusions regarding possible differences in survival between treatments.

One possible explanation for the guidance advocating dose escalation so widely is the extent of the anecdotal evidence for its effectiveness in clinical practice and the evidence (observed disease control rates of 30% with 59% of these patients remaining progression free for over 2 years after dose escalation) supports this. Another explanation is that the effectiveness of high dose imatinib as an initial treatment is assumed to also apply to escalated dosing (which may not be clinically or biologically valid). Within our study these data on initial high imatinib dosing were excluded because this represents a clinically and biologically distinct model from dose escalation upon progression, especially in terms of distinct mechanisms for primary or acquired resistance to high dose imatinib. It would not be valid to assume that these mechanisms would be the same for those receiving high-dose imatinib initially, as for those patients who receive initial 400 mg dosing, become resistant, and are subjected to dose escalation at that point.

Clinical practice may be changing to enable mutational status to be used to tailor a patient's initial imatinib dose in future. With regard to imatinib dose escalation, the mutational status of the 16 (600 mg/day) and 75 patients (800 mg/day) showing response or stable disease with escalated imatinib doses in this review was not known. Evidence of the effectiveness of imatinib dose-escalation on these patient subgroups therefore remains lacking, although the EORTC-ISG-AGITG trial results reported (using *p* values only) that wild-type KIT and exon nine mutations were significantly more likely to respond to escalated doses compared with those with exon 11 mutations \[[@CR24]\]. Even if clinical practice changes to recommend patients with exon nine or wild-type KIT receive high doses of imatinib from commencement of treatment rather than on progression at the standard dose, evidence on the effectiveness of dose escalated imatinib will still be necessary for patients who do not have these particular mutations.

Limitations {#Sec7}
-----------

The non-randomised, observational nature of the available data is prone to a range of biases (e.g. confounding). In addition, none of the studies distinguished between whether participants had shown progression or whether they had shown intolerance to imatinib at 400 mg/day. For the included sunitinib trial it was necessary to assume that the majority of the participants receiving "≤400 mg/day" had received the actual dose of 400 mg/day, rather than lower doses. No 'off-licence' treatments for GIST were considered (e.g. doses exceeding 800 mg/day or continuous daily dosing of sunitinib). Surgical interventions were also not considered, even though they may offer an important treatment option (e.g. in emergencies as part of best supportive care, or if drug treatment shrinks tumours sufficiently to enable resection).

Conclusions and Recommendations {#Sec8}
-------------------------------

This review demonstrates that although dose escalation is widely recommended within clinical guidance documents \[[@CR8]--[@CR10]\], the actual evidence for its effectiveness among the unresectable and/or metastatic GIST population after progression at the standard 400 mg/day imatinib dose is based solely on the results of several sets of observational data reported within wider RCT evidence on the effectiveness of standard versus high doses of imatinib.

Ideally, the existing evidence base could be improved with new RCT evidence, but this is unlikely to be feasible or appropriate given both the low incidence and the nature of the disease. However, well-designed, non-randomised studies could potentially help guide policy development on treatment for this population group.

Imatinib and sunitinib trialists with access to existing evidence on dose escalation outcomes (particularly for patients of differing mutational status) should consider publishing these data separately if this has not already been done, or attempt to pool existing patient-level data. Sixty-six studies were excluded from this review because they had not reported any separate information for dose escalated patients, and a further 84 studies were excluded because they did not report any information on imatinib dose (including sunitinib studies not reporting information on the prior imatinib dose received by the study population). It is therefore possible that pooling any existing unpublished patient level data could help clarify the comparative effectiveness of dose escalation upon progression on the 400 mg/day imatinib dose.
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